Aurora Cannabis Inc. (ACB, Financial) has expanded its medical product offerings by introducing new cannabis concentrates to the United Kingdom market. This marks an important step as these products are already accessible to patients in Canada and Australia.
The new offerings include two distinctive 1.2-gram resin cartridges, each developed from proprietary cultivars unique to Aurora. These targeted products are designed to address specific medical needs and broaden patient options in consuming cannabis for therapeutic purposes.
This development underscores Aurora's commitment to expanding its international medical cannabis footprint, aiming to provide patients with access to proprietary, high-quality cannabis solutions across multiple regions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Aurora Cannabis Inc (ACB, Financial) is $31.79 with a high estimate of $31.79 and a low estimate of $31.79. The average target implies an upside of 648.08% from the current price of $4.25. More detailed estimate data can be found on the Aurora Cannabis Inc (ACB) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Aurora Cannabis Inc's (ACB, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Aurora Cannabis Inc (ACB, Financial) in one year is $6.07, suggesting a upside of 42.82% from the current price of $4.25. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Aurora Cannabis Inc (ACB) Summary page.
